Zetta Genomics appoints Mark Bailey as CEO to lead drive for growth  

Previously CEO at Fendix, Mark‘s understanding of the wider medtech industry means he is well-placed to accelerate Zetta’s global momentum. 

Zetta Genomics, a pioneer in large-scale genomic data management, has appointed Mark Bailey as its chief executive officer. Bailey has been brought in to lead Zetta’s next phase of growth.  

Ludo Chapman, Chair of Zetta Genomics, commented: “We welcome Mark’s experience and vision as we continue our journey of providing clients with the unique, highly scalable and dynamic data management platform fit for the genomic era.” 

Mark Bailey, CEO at Zetta Genomics, commented on his appointment: “Zetta Genomics is ushering in a new world of genome-optimised data storage, and I am hugely excited to be joining the team at this exciting time. As the company enters the next stage of business growth, I look forward to helping Zetta make precision medicine available for every patient, by delivering real time decision support to the clinicians and scientists involved in their care.” 

Most recently CEO at Fendix, Mark led a transformation in NHS digital engagement – disrupting how service providers interact with the NHS workforce and creating powerful new revenue streams in the process. Mark has almost two decades of experience within the healthcare and science industries. He has held senior roles at numerous high-growth medtech firms – most notably Cegedim, Sciensus and Fendix Media. His deep understanding of the wider industry means he is well-placed to accelerate Zetta’s global momentum. 

Zetta has been growing quickly in the past few years, recently spurred on by a successful £2.5 million seed funding round in February 2022, with several senior appointments in the past year which cement its business strategy and lead its highly talented – and growing – team. 

Read more about Mark Bailey on our Leadership page.